PRX 07034

Drug Profile

PRX 07034

Alternative Names: PRX-07034

Latest Information Update: 15 Oct 2009

Price : $50

At a glance

  • Originator EPIX Pharmaceuticals
  • Class Nootropics; Obesity therapies
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Alzheimer's disease; Cognition disorders; Obesity

Most Recent Events

  • 01 Oct 2009 EPIX Pharmaceuticals has sold PRX 00023 to an undisclosed company
  • 11 Aug 2009 The PRX 00023 programme will be offered for sale at auction
  • 07 Nov 2007 Pharmacodynamics data from a preclinical study in weight gain and cognition disorders presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top